Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Primary Outcome Measures:

• Percentage of Participants With Virologic Rebound, (Confirmed), Plasma Human Immunodeficiency Virus - 1 (HIV-1) Ribonucleic Acid (RNA) Level >=50 Copies/mL through Week 48 [ Time Frame: Up to Week 48 ]
  Virologic rebound is defined as 1) participants who show confirmed HIV-1 RNA >= 50 copies/mL through Week 48 window or 2) participants who discontinued prematurely (irrespective of reason) for which the last available (single) HIV-1 RNA ≥ 50 copies/mL.
  
  

Secondary Outcome Measures:

• Change From Baseline in Cluster of Differentiation (CD) 4+ Cell Counts at Week 24, 48, and 96 [ Time Frame: Week 24, 48, and 96 ]
  Participant's immunological status will be assessed by CD4+ cell count at Weeks 24, 48, and 96.
  
  
• Percentage of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs) of Grade 3 and 4, and Premature Discontinuations due to AEs [ Time Frame: Baseline up to Week 24, 48, and 96 ]
  An AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Grade 3 (Severe) events are symptoms causing inability to perform usual social & functional activities. Grade 4 (Life-threatening) events are Symptoms causing inability to perform basic self-care functions or Medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.
  
  
• Percentage of Participants With Resistance to ARVs and Type of Resistance in Participants with Virologic Rebound [ Time Frame: Baseline, Week 24, 48 and 96 ]
  Presence of emerging Resistance-Associated Mutations by ARV-class in the HIV-virusses.
  
  
• Change From Baseline in Serum Creatinine, Estimated Glomerular Filtration Rate for Creatinine Clearance (eGFRcr), and eGFR for Cystatin-C Clearance (eGFRcyst) at Week 24, 48 and 96 [ Time Frame: Up to Weeks 24, 48, and 96 ]
  The change from baseline in serum creatinine, eGFRcr (by Cockcroft-Gault and by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] methods) and eGFRcyst (by CKD-EPI method) at Week 24, 48 and 96 will be assessed.
  
  
• Change from Baseline in Renal Biomarkers at Weeks 24, 48, and 96 [ Time Frame: Baseline and Week 24, 48, and 96 ]
  Renal biomarkers are retinol binding protein [RBP] and beta-2-microglobulin
  
  
• Percent Change From Baseline in Spine and Hip Bone Mineral Density (BMD) at Weeks 24, 48, and 96 [ Time Frame: Baseline and Weeks 24, 48, and 96 ]
  BMD measured by DXA (dual energy xray absorptiometry) at lumbar spine, (L1-L4) and for total hip (femoral neck, trochanter and inter-trochanter areas). The data will be analyzed for participants participating in bone substudy.
  
  
• Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL at Week 24, 48 and 96 per FDA Snapshot Approach [ Time Frame: Week 24, 48 and 96 ]
  FDA Snapshot approach analysis is based on the last observed viral load data within the Week 24, 48 and 96 window: virologic response is defined as HIV-1 RNA <50 copies/mL (observed case); missing HIV-1 RNA is considered as non-response.
  
  
• Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL at Weeks 24, 48, and 96 per TLOVR algorithm [ Time Frame: Week 24, 48, and 96 ]
  Time to loss of virologic response algorithm (TLOVR) requires sustained HIV-1 RNA < 50 copies/mL; confirmed HIV-1 RNA more than or equal to (>=) 50 copies/mL is considered as non-response (rebound); participant is considered non-responder after permanent discontinuation.
  
  

This is a randomized (study medication assigned to participants by chance), active-controlled (study in which the experimental treatment or procedure is compared to a standard treatment or procedure), open-label (participants and researchers are aware about the treatment, participants are receiving), multicenter (when more than 1 hospital or medical school team work on a medical research study), study in virologically-suppressed, HIV-1 infected adult participants. The study will include a Screening Period of approximately 30 days (up to maximum 6 weeks), a controlled Treatment Period of 48 weeks, an Extension Phase of 48 weeks. All eligible participants will be randomly assigned to receive either current treatment regimen - a bPI (limited to DRV with low-dose ritonavir [rtv] or COBI, atazanavir [ATV] with rtv or COBI, or lopinavir [LPV] with rtv) combined with FTC/TDF, or experimental treatment regimen - D/C/F/TAF once-daily single-tablet for 48 weeks. After completion of week 48, participants assigned to the experimental treatment will continue with D/C/F/TAF in the extension phase up to week 96 . Participants who continued their current regimen will receive the experimental treatment (if all criteria are fulfilled) at week 52 up to week 96. As from Week 96, all participants will be given the option to continue D/C/F/TAF treatment, if they wish and if they continue to benefit from it until D/C/F/TAF becomes commercially available and is reimbursed, or can be accessed through another source in the country where he/she is living,or until the sponsor terminates clinical development. A bone investigation substudy will be performed at selected study sites, to assess bone biomarkers and energy x-ray absorptiometry (DXA) scans, in approximately 300 participants (200 in the D/C/F/TAF treatment arm versus 100 in the control arm) who provide informed consent for the substudy.